Home / NYT / CureVac’s mRNA vaccine reaches an efficacy of just 47 percent in a clinical trial.

CureVac’s mRNA vaccine reaches an efficacy of just 47 percent in a clinical trial.


By BY CARL ZIMMER from NYT Health https://ift.tt/2S3JZhJ
CureVac’s mRNA vaccine reaches an efficacy of just 47 percent in a clinical trial. CureVac’s mRNA vaccine reaches an efficacy of just 47 percent in a clinical trial. Reviewed by Saima Kiyani on June 16, 2021 Rating: 5

You May Also Like

No comments:

Subscribe to: Post Comments ( Atom )
Powered by Blogger.